U.S. markets open in 21 minutes

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.5200-0.1300 (-3.56%)
At close: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close3.6500
Bid3.5200 x 1400
Ask3.8000 x 1800
Day's Range3.4200 - 3.6500
52 Week Range3.2900 - 11.4700
Avg. Volume64,825
Market Cap49.218M
Beta (5Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)-0.5700
Earnings DateNov 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for RVPH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Reviva Pharmaceuticals Holdings
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    last monthMorningstar
View more
  • Zacks Small Cap Research

    RVPH: Phase III Initiation Before Year End

    By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 15, 2021, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) announced third quarter 2021 financial and operational results and filed its Form 10-Q with the SEC for the period ending September 30, 2021. Reviva is on the cusp of launching its Phase III

  • GlobeNewswire

    Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

    - Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end - - Additional Phase 3 trial evaluating the long-term safety of brilaroxazine in adult patients with schizophrenia expected to begin by year-end - - $33.5 Million in Cash as of September 30, 2021 - CUPERTINO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage ph

  • GlobeNewswire

    Reviva Pharmaceuticals to Present at the Upcoming Benzinga Healthcare Small Cap Conference

    CUPERTINO, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Benzinga Healthcare Small Cap Conference as well as parti